Shirkadda dawooyinka ee Japan Otsuka (Otsuka) ayaa dhawaan heshay war wanaagsan oo ku saabsan dhinacyada sharciyeynta Mareykanka, FDA waxay ansixisay ka hortagga kansarka dawada cusub ee Lo 3 bilood ka hornsurf (trifluridine / tipiracil, FTD / TPI) waxaa loo isticmaalaa in lagu daweeyo bukaanada qaba kansarka mindhicirka ee metastatic (mCRC) kuwaas oo aan ka jawaabin daawaynta kale (kemotherapy iyo biotherapy).
Lonsurf (koodka horumarinta TAS-102) waa dawo cusub oo antimetabolite ah, taas oo ka kooban anti-tumor nucleoside analog FTD (trifluridine) iyo thymidine fosforylase inhibitor TPI (tipiracil). Waxaa ka mid ah, FTD waxay si toos ah ugu beddeli kartaa thymine si toos ah DNA-da laba-geesoodka ah inta lagu jiro soo-celinta DNA-da, taas oo keenta cillad DNA-da oo faragelisa isku-darka unugyada kansarka; TPI waxay joojin kartaa phosphorylase thymus ee la xidhiidha burburka FTD waxayna yaraynaysaa xaalufka FTD, Ilaali xoogga dhiiga ee FTD.
Lonsurf’s approval was based on positive data from an international, randomized, double-blind phase III study RECOURSE. The study involved 800 patients with previously treated metastatic kansarka mindhicirka (mCRC). In the study, patients were randomized to receive Lonsurf + best supportive therapy (BSC) or placebo + BSC until the condition deteriorated or the side effects became unbearable. The data showed that the overall survival of the Lonsurf treatment group was significantly longer than that of the placebo group (OS: 7.1 months vs 5.3 months), while progression-free survival was also significantly longer (PFS: 2 months vs 1.7 months) , Reached the primary and secondary endpoints of the study. In terms of safety, the most common side effects of the Lonsurf treatment group include anemia, weakness, extreme fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and fever.
Markii hore, Lonsurf waxaa ansixiyay hay'adaha xakamaynta Japan bishii Maarso 2014; Yurub gudaheeda, Otsuka waxay u gudbisay dalabka Lonsurf midowga yurub bishii Maarso ee sanadkan, shirkadduna waxay heshiis la saxiixatay lammaanaheeda Servier Wixii heshiiskii ahaa $ 130 milyan, Servier wuxuu mas'uul ka noqon doonaa iibinta ganacsiga ee Lonsurf ee qaaradda Yurub. .
Suuqa daaweynta kansarka mindhicirka (CRC) ayaa gaari doona $ 9.4 bilyan sanadka 2020.
Sida laga soo xigtay warbixinta cilmi baarista ee ay soo saartay shirkadda cilmi baarista suuqa adduunka ee GBI Research, suuqa daaweynta kansarka mindhicirka adduunka (CRC) wuxuu ilaalin doonaa koror yar oo xasilloon sannadaha soo socda (2014-2020), oo gaaraya 9.4 bilyan oo doolarka Mareykanka ah sannadka 2020. muddada saadaasha, heerka kororka sanadlaha isku dhafan (CAGR) wuxuu ahaa 1.8%, qiimaha suuqa ee suuqa 2013 wuxuu ahaa $ 8.3 bilyan.
Warbixintu waxay tilmaantay in kobacani uu inta badan ka dhici doono siddeed waddan oo waaweyn oo horumaray, oo ay ku jiraan Maraykanka, Japan, Kanada, iyo shan waddan oo Yurub ah (Ingiriiska, Faransiiska, Jarmalka, Spain, iyo Talyaaniga). Sannadkii 2013, Maraykanku wuxuu lahaa saamiga ugu badan ee suuqa daawaynta kansarka mindhicirka adduunka (CRC), oo ka dhigan 44.1%, waxaa ku xiga Japan (14.7%) iyo Jarmalka (11.9%), iyo Spain (4.1%) oo leh suuqa ugu hooseeya wadaag. Wadamadan ayaa la filayaa inay ku koraan si tartiib tartiib ah, marka laga reebo Japan, oo ku kori doonta xawaare aad u dheereeya (CAGR ee 5%).
Warbixinta ayaa tilmaamtay inta lagu jiro mudada saadaasha, dawada Roche blockbuster Avastin (magaca guud: bevacizumab, bevacizumab) iyo Merck (Merck KGaA) daroogada weyn ee loo yaqaan 'Erbitux' (magaca guud: cetuximab), Cetuximab) shatiyadaha suuqyada waaweyni dhacayaan, ayaa kor u qaadi doona aqbalaadda suuqa ee biosimilars-ka qiimaha jaban, taas oo xaddidi doonta koritaanka suuqa daaweynta kansarka mindhicirka ee mindhicirka adduunka. Dawada jimicsiga ee Roche Xeloda (Xeloda, magaca guud: capecitabine, capecitabine) dawooyinka guud ee ku taxan suuqyada waaweyn ayaa la filayaa inay sidoo kale xaddido koritaanka suuqa daaweynta kansarka mindhicirka ee malawadka.
Si kastaba ha ahaatee, falanqeeyaha GBI Saurabh Sharma ayaa tilmaamay in xitaa haddii patent-ka Avastin uu dhacayo, daawadu ay sii wadi doonto booska ugu horreeya ee suuqa daaweynta kansarka mindhicirka ee caalamiga ah (CRC) ilaa 2020. Saurabh wuxuu sharraxay in Avastin hadda si weyn loo isticmaalo safka koowaad iyo labaad. -daawaynta khadka ee kansarka mindhicirka, iyadoon loo eegin heerka K-Ras ee bukaanka. In kasta oo laxidhiidha dawooyinka kobaca epidermal-ka (EGFR) inhibitors loo suuq geeyey daawaynta nooca duurjoogta ah ee K-Ras burooyinka ; Avastin wuxuu sii wadi doonaa inuu xukumo suuqiisa marka la daaweynayo nooca duurjoogta ah ee loo yaqaan 'K-Ras' iyo nooca burooyinka mutant.
The report points out that Bayer ‘s new oral anti-cancer drug Stivarga (regorafenib) is expected to be one of the biggest drivers of growth in the global colorectal cancer (CRC) treatment market. This is mainly due to the expected clinical treatment expansion of the drug as a maintenance treatment The drug is used for the first-line treatment of metastatic colorectal cancer (mCRC) that has had liver metastases removed. Stivarga is an oral multi-kinase inhibitor currently listed in major markets such as the US, EU, and Japan. In addition, Japan ‘s Dapeng Pharmaceutical ‘s anticancer drug Lonsurf (TAS-102) was approved for third- and fourth-line treatment in Japan in 2014, and Amgen ‘s monoclonal antibody Vectibix (panitumumab) was also approved by the United States. And EU approved for first-line treatment. The market acceptance of these new drugs will promote the growth of the global therapeutic market.
Warbixinta ayaa sidoo kale tilmaamtay in inta lagu jiro mudada saadaasha (2014-2020), dawooyin badan oo dhuumaha cusub ah la filayo inay ku soo degaan suuqa, oo ay ku jiraan Lilly's monoclonal antibody Cyramza (ramucirumab), Boehringer Ingelheim's triple angiokinase inhibitor nintedanib, XBiotech The monoclonal antibody Xilonix . Si kastaba ha noqotee, daawooyinkani waxay soo gali doonaan daaweynta labaad ee adag iyo daaweynta saddexda iyo afaraad mana saameyn weyn ku yeelan doonto suuqa oo dhan. Daawooyinka la calaamadeeyay ee hadda ku jira suuqa ayaa sii wadi doona inay ku raaxeystaan xukunka suuqa maadaama ay ku jiraan daaweyn hore iyo faa'iido badan oo safka hore ah.
